Pfizer Inc last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 27, 2026): revenue of $16.6 billion (-0.4% year over year) and diluted EPS of $0.56. It usually reports 34–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 2, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 3, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
37 days after quarter end
|
Q3 FY2026
ended Sep 27, 2026
|
16,583
-0.4%
|
3,242
-8.4%
|
0.56
-9.7%
|
|
Aug 4, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 28, 2026
|
15,034
+2.6%
|
-248
-108.5%
|
-0.04
-107.8%
|
|
May 5, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 29, 2026
|
14,451
+5.4%
|
2,687
-9.4%
|
0.47
-9.6%
|
|
Feb 3, 2026
34 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
17,557
-1.2%
|
-1,648
-502.0%
|
-0.29
-500.6%
|
|
Nov 4, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 28, 2025
|
16,654
-5.9%
|
3,541
-20.7%
|
0.62
-20.5%
|
|
Aug 5, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 29, 2025
|
14,653
+10.3%
|
2,910
+6997.6%
|
0.51
+5000.0%
|
|
Apr 29, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 30, 2025
|
13,715
-7.8%
|
2,967
-4.8%
|
0.52
-5.5%
|
|
Feb 4, 2025
35 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
17,763
+21.9%
|
410
+112.2%
|
0.07
+112.2%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PFE (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 78003
- Former names
- PFIZER INC (until Nov 3, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.